Expedited Programs and New Approvals in Oncology (2013 – Present)
Using publicly available data from review documents on Drugs@FDA, Friends created this dashboard to show how four expedited programs impact the time it takes for a drug or biologic to be approved.
This dashboard displays data on original therapeutic agents approved for use in oncology since January 2013 when the most recent expedited pathway, breakthrough therapy designation (BTD), became available for use. Supplemental approvals and supportive agents were excluded. Please note the review documents for some drugs/biologics approved since January 2013 are not yet available online. These approvals were excluded from the dashboard and will be added as their review documents become available.
Last Updated: June 30, 2021.